Genentech

San Francisco, United States Founded: 1976 • Age: 50 yrs Acquired By Roche
RD company focused on manufacturing drugs for multiple therapeutic areas
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products 2 Services tracked
Competitors 11 Brand Intelligence

About Genentech

Genentech is a company based in San Francisco (United States) founded in 1976 was acquired by Roche in March 2009. Genentech has completed 5 acquisitions, including Jecure Therapeutics, MyVisionTrack and RQX Pharmaceuticals. Genentech offers products and services including Medicines and Clinical Trials. Genentech operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.

  • Headquarter San Francisco, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Genentech, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $404.2 K (USD), Grant

    Sep 22, 2023

  • Investors
    Roche

    & 1 more

  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    Roche

    (Mar 12, 2009)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Genentech

Genentech offers a comprehensive portfolio of products and services, including Medicines and Clinical Trials.

Product name locked
Category locked
Primary

Treatments for oncology and other diseases

Product name locked
Category locked
Locked

Conducts studies for new therapies and patient support

People of Genentech

Headcount 10000+
Employee Profiles 769
Board Members and Advisors 5
Employee Profiles
People
Melanie Gross
Associate General Counsel & Practice Group Leader, Healthcare Law Group
People
Jodie Peake
Senior Marketing Manager, Immunology And Foundational Products
People
Stephanie Wang
Director/us Commercial Lead, New Product Commercialization - Oncology And Immunology Pipeline
People
Huy Ngo
Clinical Pharmacology Scientist

Unlock access to complete

Board Members and Advisors
people
Alan Hippe
Director

Unlock access to complete

Funding Insights of Genentech

Investors in Genentech

Genentech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Roche and HHS.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Locked Locked Locked
Pharmaceuticals and diagnostics kits are developed for various diseases.
Locked Locked Locked
Premium access

Investor details for Genentech

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Genentech

Genentech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Jecure Therapeutics, MyVisionTrack and RQX Pharmaceuticals.

Investments
Premium access

Investment portfolio details for Genentech

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapeutics for NASH and liver fibrosis are discovered and developed.
Locked Locked 2015 Locked
Selective estrogen receptor degraders are developed for breast cancer treatment.
Locked Locked 2013 Locked
Novel antibiotics for community and hospital infections are developed.
Locked Locked 2010 Locked
Premium access

Complete acquisition details for Genentech

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Genentech

Premium access

Detailed financials for Genentech

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Genentech Comparisons

Genentech Primary company
Description
R&D company focused on manufacturing drugs for multiple ther...
Location
San Francisco, United States
Founded Year
1976
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Genentech

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Genentech

Genentech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Pharmaceutical products are manufactured and marketed worldwide.
Locked Locked Locked
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
Locked Locked Locked
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Locked Locked Locked
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
Locked Locked Locked
Traditional pharmaceutical medicines are developed for multiple health fields.
Locked Locked Locked
Developer of drugs for the treatment of multiple disorders
Premium access

Detailed competitors of Genentech

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Genentech

Premium access

Complete news archive for Genentech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Genentech

Genentech was founded in 1976 and raised its 1st funding round 47 years after it was founded.

Genentech is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Genentech was founded in 1976 in San Francisco, United States, as a biotechnology firm. Research and development efforts are directed toward manufacturing pharmaceutical products across multiple therapeutic areas, including oncology, immunology, neurology, metabolism, infectious diseases, and ophthalmology. Clinical trial information services are also offered to support medical research and development activities in the sector.

Genentech's top competitors include Merck, Roivant Sciences and AbbVie.

Genentech offers Medicines and Clinical Trials.

Genentech has made 5 acquisitions, including Jecure Therapeutics, MyVisionTrack, and RQX Pharmaceuticals.

Genentech has 2 investors. Key investors include Roche, and HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available